Development of immuno-oncology drugs — from CTLA4 to PD1 to the next generations
Crossref DOI link: https://doi.org/10.1038/nrd.2015.35
Published Online: 2016-03-11
Published Print: 2016-04
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Hoos, Axel
Text and Data Mining valid from 2016-03-11
Article History
First Online: 11 March 2016
Competing interests
: A.H. is an employee and shareholder of GlaxoSmithKline and Director of the Board and shareholder of Imugene.